Table 3 summarizes the fundamental difficulties in developing and implementing GPR120 agonist-based treatments for metabolic disorders in obesity and indicates likely future strategies in this area. The gene discussed is FFAR4; the disease is obesity due to melanocortin 4 receptor deficiency.